News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

iLiAD Biotechnologies, Inserm And Inserm Transfert SA, And Institut Pasteur de Lille Enter Scientific Collaboration And Worldwide License Agreements For Vaccine Technology


1/9/2014 8:19:35 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK & PARIS & LILLE, France--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), the French National Institute of Health and Medical Research (Inserm) subsidiary, Inserm Transfert SA, and Institut Pasteur de Lille (IPL) today announced the signing of scientific collaboration and worldwide license agreements for live attenuated Bordetella pertussis vaccine technology, including BPZE1, developed by the laboratory of Professor Camille Locht. This license agreement covers patent rights from Institut Pasteur de Lille, Inserm, National University of Singapore1 and National University of Ireland Maynooth2.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES